Sign In
Buy ABT
$90.53
+2.76 (+3.14%)
At Close: Jun 23, 2026
Abbott (ABT) to Commence Limited Release of EleCare Soon
10:32am, Thursday, 26'th May 2022
Abbott's (ABT) release of limited quantities of EleCare branded specialty formulas to be free of charge to children in need.
House lawmakers take on baby-formula shortage: ‘We expect answers from the FDA, Abbott’
07:58pm, Wednesday, 25'th May 2022 MarketWatch
Democratic and Republican lawmakers on Wednesday are putting a spotlight on makers of baby formula, the Biden administration and industry experts due to an ongoing formula shortage, with two House hea
Baby formula crisis: Products from closed plant won't hit shelves until at least mid-July, Abbott says
06:35pm, Wednesday, 25'th May 2022
Baby formula from Abbott Nutrition's shuttered manufacturing facility will not hit shelves until mid-July, an official says.
2 Dividend Kings That Are Soundly Beating the Market in 2022
03:00pm, Wednesday, 25'th May 2022 The Motley Fool
These stocks could be good places to park your money.
House lawmakers take on baby-formula shortage: ‘We expect answers from the FDA, Abbott'
11:42am, Wednesday, 25'th May 2022
Democratic and Republican lawmakers on Wednesday were putting a spotlight on makers of baby formula, the Biden administration, and industry experts due to an ongoing shortage, with two House hearings
Abbott to restart production of EleCare formula on June 4
08:50am, Wednesday, 25'th May 2022
Abbott Laboratories ABT, -1.10% said Tuesday it plans to restart manufacturing formula at its plant in Sturgis, Mich., on June 4, and it will prioritize production of EleCare, a hypoallergenic, amino
Abbott (ABT) Transcatheter Valve Devices' Study Data Favorable
03:20pm, Tuesday, 24'th May 2022 Zacks Investment Research
Abbott's (ABT) study data presented at EuroPCR 2022 reinforces the company's commitment to offering structural heart solutions, supported by clinical evidence that exceeds existing standards of care.
Abbott (ABT) Transcatheter Valve Devices' Study Data Favorable
12:48pm, Tuesday, 24'th May 2022
Abbott's (ABT) study data presented at EuroPCR 2022 reinforces the company's commitment to offering structural heart solutions, supported by clinical evidence that exceeds existing standards of care.
Baby-formula industry was primed for disaster long before key factory closed down
02:12pm, Monday, 23'rd May 2022 MarketWatch
Government-granted monopolies, supply-chain problems, and profit-maximizing behavior contributed to shortages of vital food for infants.
Abbott CEO apologizes for baby formula shortage, promises production ramp-up
09:41pm, Sunday, 22'nd May 2022 MarketWatch
Abbott Laboratories Chief Executive Robert Ford apologized Saturday for his company’s role in the nationwide shortage of baby formula and promised production will ramp up again in June.
The Wall Street Journal: Abbott CEO apologizes for baby formula shortage, promises production ramp-up
05:41pm, Sunday, 22'nd May 2022
Abbott Laboratories Chief Executive Robert Ford apologized Saturday for his company's role in the nationwide shortage of baby formula and promised production will ramp up again in June.
'We're sorry' for U.S. baby formula shortage, Abbott CEO Ford says in Washington Post op-ed
05:25pm, Saturday, 21'st May 2022
The apology by Abbott's CEO came after President Joe Biden signed a new law to deal with the baby formula shortage.
What Could the Baby Formula Shortage Mean for Abbott Laboratories?
10:34am, Saturday, 21'st May 2022 The Motley Fool
There are more stormy waters ahead, but they might not be a problem in the end.
What Could the Baby Formula Shortage Mean for Abbott Laboratories?
06:34am, Saturday, 21'st May 2022
There are more stormy waters ahead, but they might not be a problem in the end.
Abbott Is A Great Company, But Its Price Makes It Unattractive
06:03pm, Friday, 20'th May 2022
Abbott is dealing with some significant pressure due to the baby formula shortage. The shares of Abbott are trading for a price 22% lower than the 52 weeks high.
